Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized. Multicenter, Double-Blind, Placebo-Controlled Safety, Tolerability, and Efficacy Study of PLX-200 in Participants With Mild-to-Moderate Juvenile Neuronal Ceroid Lipofuscinosis (CLN3) Disease

NCT04637282 is registered in ClinicalTrials.gov with Polaryx Therapeutics, Inc. as lead sponsor.

NCT NCT04637282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04637282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized. Multicenter, Double-Blind, Placebo-Controlled Safety, Tolerability, and Efficacy Study of PLX-200 in Participants With Mild-to-Moderate Juvenile Neuronal Ceroid Lipofuscinosis (CLN3) Disease
Lead sponsor
Polaryx Therapeutics, Inc.
Phase
Phase 3
Overall status
Withdrawn
Start date
November 1, 2026
Completion date
December 31, 2026
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

juvenile neuronal ceroid lipofuscinosis